Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)

Abstract


 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses ELX-TEZ-IVA (Trikafta) and ELX 100 mg, TEZ 50 mg, IVA 75 mg (combination tablet), and 150 mg IVA (tablet); oral.
 Indication: Treatment of cystic fibrosis in patients aged ≥ 12 years who have at least 1 F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.